The company was established in July 2014 and is based in Évry, southern suburbs of Paris, France.
Gour Medical’s main idea is to allow mature pets to benefit from the progress of human medicine, giving them the opportunity to live longer and enjoy healthier lives.
Since its creation, a team of recognized experts from the animal health industry has joined Gour Medical to create an ecosystem able to identify products derived from technologies originally developed for humans.
Gour Medical’s expertise in identifying and selecting drug candidates and maximizing their clinical and commercial potential convinces human biopharmaceutical companies to entrust us with developing their products for animal health use. This has resulted in a series of exclusive and worldwide licenses.
Gour Medical History
Gour Medical SA created in Switzerland in the canton of Zug with a capital of CHF 100,000
Gour Medical SA signs an exclusive worldwide licensing agreement with the Swiss pharmaceutical company Actelion (SIX : ATLN) for Gour-713, an Orexine receptor antagonist to treat stress and anxiety in pets.
Gour Medical SA signs an exclusive worldwide license, manufacturing, distribution and service agreement with the German company Solmic Research GmbH, specializing in innovative systems for the development of products based on natural cannabinoids.
Gour Medical SA signs an exclusive licensing agreement with world leader in animal health diagnostics: Idexx Laboratories Inc. (NASDAQ: IDXX) for the development of an anti-IgE monoclonal antibody to treat atopic dermatitis in dogs.
Gour Medical SA signs an exclusive manufacturing, distribution and marketing agreement with the UK company Medicom Healthcare Limited for the marketing of high-quality ophthalmic products for pets.
GOUR Medical, animal health specialist, lists on the Marché Libre Euronext Paris
Transfer of the corporate headquarter to France
Focus on medical cannabis for companion animals